Decoding Great Point Partners’ $1.7 Billion Founder-First Healthcare Playbook

GREENWICH, Conn. – October 27, 2026 – The era of the smash-and-grab healthcare buyout is facing an existential threat. With the Federal Trade Commission and the Department of Justice tightening the regulatory screws on private equity consolidation, the structural mechanics of medical acquisitions are being forced to evolve. In a sector where capital is abundant but operational expertise is scarce, the new currency of dealmaking is collaboration.

This shifting paradigm was underscored this week when Great Point Partners, a Greenwich-based private investment firm managing approximately $1.7 billion, secured a spot on Inc.’s 2026 Founder-Friendly Investors list for the fourth consecutive year. The recognition, which relies heavily on direct feedback and performance data from entrepreneurs who have partnered with investment firms, highlights a broader systemic transformation in how private equity operates within the life sciences and healthcare infrastructure spaces.

Since its inception in 2003, Great Point Partners has financed more than 100 growing healthcare companies. But as the engines that power global healthcare undergo rapid digitalization and structural realignment, the firm’s sustained recognition points to a deeper strategic playbook—one that attempts to rewrite the often-contentious relationship between private equity sponsors and founding teams.

"At Great Point, our approach has always centered on building lasting partnerships with entrepreneurs who are driving innovation across the health care industry," said Jeffrey Jay, Founder and Managing Partner of Great Point Partners, in a statement regarding the accolade. "We believe the strongest outcomes come from combining our experience and capabilities with the vision and leadership of the founders and management teams we back."

The Antidote to the Predatory Buyout

For decades, the standard private equity playbook in healthcare relied heavily on leveraged roll-ups—acquiring a platform company, aggressively cutting costs, and bolting on smaller competitors to build scale before a lucrative exit. However, this model has increasingly drawn the ire of both federal regulators and healthcare professionals, who argue that aggressive financial engineering can degrade patient care and stifle long-term innovation.

Great Point Partners has deliberately charted a different course, focusing on middle-market growth equity and buyouts with enterprise values typically ranging between $25 million and $250 million. Rather than strictly deploying financial leverage, the firm leverages structural support systems. By maintaining a dedicated CEO Board of leading industry executives and a Medical Advisory Board comprised of physicians and scientists, the firm positions itself as an operational co-pilot rather than a mere financial overlord.

This infrastructure allows the firm to navigate the highly specialized and heavily regulated sub-sectors of biopharmaceutical services, alternate site care, medical device contract manufacturing, and healthcare information technology. By providing founders with direct access to clinical and executive expertise, the firm mitigates the culture clashes that historically doom healthcare acquisitions.

"At Great Point we believe that strong partnerships begin well before an investment is made," noted Rohan Saikia, Managing Director at the firm. "We prioritize building relationships with founders early, taking the time to understand their businesses, ambitions and challenges. Whether a company is ready to explore a partnership today or several years down the road, our goal is to be a trusted resource to entrepreneurs as they navigate the next stage of growth."

Decoding the Accolade Economy in Private Equity

To the uninitiated, an appearance on a magazine's annual list might seem like a mere public relations victory. However, in the hyper-competitive landscape of private equity sourcing, reputation-based badges serve as critical marketing levers.

Inc.’s methodology requires going straight to the source. The publication surveys entrepreneurs who have sold stakes to or partnered with private equity and venture capital firms, gathering data on how their companies performed post-investment and whether the investors acted as collaborative partners. While firms do not pay to be considered for the list—though standard licensing fees apply for post-award marketing materials—the barrier to entry remains high, requiring overwhelmingly positive feedback from the founders themselves.

For Great Point Partners, this verified reputation is a vital asset as it actively deploys capital from its GPP IV fund, which closed oversubscribed at $307 million in 2021. As macroeconomic headwinds, including elevated interest rates, make debt-fueled acquisitions more expensive, private equity firms are increasingly reliant on proprietary deal flow. Founders of successful mid-market healthcare companies are now acutely aware of the risks associated with choosing the wrong financial sponsor. They demand partners who can shepherd them through complex regulatory environments and technological shifts, such as the integration of artificial intelligence in drug discovery and the migration of care from hospitals to alternate sites.

By consistently securing third-party validation of its founder-friendly approach, Great Point Partners effectively lowers its customer acquisition cost for new deals. When competing against larger, diversified mega-funds, the firm's specialized focus and documented history of founder retention become powerful differentiators at the negotiating table.

Scaling Specialized Care Amid Macro Headwinds

Ultimately, the efficacy of any private equity strategy is measured in returns and operational growth. Great Point Partners’ hybrid approach—managing both private equity vehicles and a public life sciences strategy via its BioMedical Value Fund—provides a unique vantage point on the healthcare ecosystem, allowing the firm to identify trends in public markets and apply them to private investments.

The firm's recent track record suggests that the collaborative model yields substantial dividends. Public pension fund disclosures provide a rare glimpse into the firm's historical performance. Data from the California Public Employees' Retirement System (CalPERS) indicated that Great Point Partners III generated a net internal rate of return (IRR) of 17.0% as of mid-2023, a figure that remains highly competitive within the specialized healthcare private equity benchmark.

This performance is driven by strategic, high-growth investments. In recent years, the firm has backed companies like Arcadian Healthcare, a provider of integrated care services, and Sperogen, a precision medicine company. It also successfully navigated the exit of CorEvitas, a provider of real-world evidence for autoimmune diseases, which was acquired by Thermo Fisher Scientific for $912.5 million following Great Point's initial investment and subsequent growth initiatives.

These transactions highlight a deliberate focus on the underlying engines of healthcare—the supply chains, data systems, and contract manufacturing pipelines that operate behind the scenes of direct patient care. As the global economy continues its structural shift toward automated manufacturing and digital infrastructure, healthcare IT and medical device production represent critical frontiers of competition.

By prioritizing the vision of the entrepreneurs building these systems, Great Point Partners is not just navigating the current regulatory and economic headwinds; it is actively shaping the architecture of the next generation of healthcare delivery. As the industry moves further away from the aggressive financial engineering of the past, the firm's $1.7 billion playbook proves that aligning investor capital with founder vision is not merely a friendly gesture, but a fundamental requirement for sustainable growth in the modern medical economy.